Psychosis in Parkinson’s disease: how should we treat it?

References

• Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain123(Pt 4), 733–745 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch. Neurol.56(5), 595–601 (1999).
   PubMed Web of Science ®Google Scholar
• Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.70(6), 734–738 (2001).
   PubMed Web of Science ®Google Scholar
• Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatr.70(6), 727–733 (2001).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J. Am. Geriatr. Soc.39(7), 708–716 (1991).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Managing psychosis in patients with Parkinson’s disease. N. Engl. J. Med.340(10), 801–803 (1999).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology45(4), 669–671 (1995).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc.48(8), 938–942 (2000).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology57(11), 2078–2082 (2001).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roldan S, Navarro E, Mateo D. Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson’s disease. Rev. Neurol.36(5), 401–404 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Pappert EJ, Blasucci LM et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology50(2), 515–517 (1998).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA284, 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Rascol O BD, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N. Engl. J. Med.342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Bracco F, Battaglia A, Chouza C et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs18(11), 733–746 (2004) [erratum appears in CNS Drugs19(7), 633 (2005)].
   Google Scholar
• Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst. Rev.2, CD000235 (2000).
   Google Scholar
• Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia41(5), 565–574 (2003).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.15(2), 201–211 (2000).
   PubMed Web of Science ®Google Scholar
• Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr. Opin. Neurol.14(4), 499–504 (2001).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology55(6), 789–794 (2000).
   PubMed Web of Science ®Google Scholar
• Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.12(3), 364–369 (2000).
   PubMed Web of Science ®Google Scholar
• Merims DSH, Balas M, Peretz C, Giladi N. Rater-blinded, prospective study comparing the therapeutic benefit of clozapine vs. quetiapine on psychosis in patients with Parkinson’s disease. Presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders (2005).
   Google Scholar
• Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol.27(4), 153–156 (2004) [Erratum appears in Clin. Neuropharmacol.27(5), 256 (2004)].
   PubMed Web of Science ®Google Scholar
• Juncos JL, Roberts VJ, Evatt ML et al. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov. Disord.19(1), 29–35 (2004).
   PubMed Web of Science ®Google Scholar
• Mancini F, Tassorelli C, Martignoni E et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin. Neuropharmacol.27(1), 33–37 (2004).
   PubMed Web of Science ®Google Scholar
• Ondo W. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov. Disord. (2004).
   PubMedGoogle Scholar
• Rabey JM, Prohorov T, Miniovich A, Klein C. The effect of quetiapine in Parkinson’s disease (PD) psychotic patients: a double-blind labelled study of 3 months duration. Presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders (2005).
   Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin. Neuropharmacol.27(1), 4–5 (2004).
   Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA294(15), 1934–1943 (2005).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol.13(3), 243–248 (1983).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol.60(12), 1745–1748 (2003).
   PubMed Web of Science ®Google Scholar
• Poewe W. Psychosis in Parkinson’s disease. Mov. Disord.18(Suppl. 6), 80–87 (2003).
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356(9247), 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr. Med. Res. Opin.18(5), 258–264 (2002).
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol. Sci.23(1), 41–43 (2002).
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin. Neuropharmacol.25(2), 107–110 (2002).
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord.16(6), 1171–1174 (2001).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314 (1994).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatr.76(7), 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry19(1), 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatr.72(6), 708–712 (2002) [Erratum appears in J. Neurol. Neurosurg. Psychiatry73(3), 354 (2002)].
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Burn DJ, Rowan EN et al. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int. J. Geriatr. Psychiatry20(10), 938–944 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18(10), 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• Fahn S ER, Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. Recent Developments in Parkinson’s Disease. Fahn S, Marsden CD, Calne DB, Goldstein M (Eds). (11), 153–163 (1987).
   Google Scholar
• Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav. Brain Sci.28(6), 737–757; discussion 757–794 (2005).
   PubMed Web of Science ®Google Scholar
• Bergman J, Brettholz I, Shneidman M, Lerner V. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer’s type. Clin. Neuropharmacol.26(2), 88–92 (2003).
   PubMed Web of Science ®Google Scholar